Laman UtamaSNG • LON
add
Synairgen plc
Tutup sebelumnya
GBX 4.71
Julat hari
GBX 4.37 - GBX 4.75
Julat tahun
GBX 3.00 - GBX 10.88
Permodalan pasaran
8.93J GBP
Bilangan Purata
162.56K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
LON
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(GBP) | Jun 2024info | Perubahan T/T |
---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 1.95J | -29.14% |
Pendapatan bersih | -1.63J | 31.28% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | — | — |
EBITDA | -1.95J | 28.75% |
Kadar cukai berkesan | 10.92% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
(GBP) | Jun 2024info | Perubahan T/T |
---|---|---|
Pelaburan tunai dan jangka pendek | 8.59J | -19.19% |
Jumlah aset | 10.64J | -43.12% |
Jumlah liabiliti | 1.08J | -60.69% |
Jumlah ekuiti | 9.56J | — |
Syer tertunggak | 201.37J | — |
Harga kepada buku | 0.94 | — |
Pulangan pada aset | -45.90% | — |
Pulangan pada modal | -51.07% | — |
Aliran Tunai
Perubahan bersih dalam tunai
(GBP) | Jun 2024info | Perubahan T/T |
---|---|---|
Pendapatan bersih | -1.63J | 31.28% |
Tunai daripada operasi | -1.84J | 30.36% |
Tunai daripada pelaburan | 882.00K | 88,100.00% |
Tunai daripada pembiayaan | — | — |
Perubahan bersih dalam tunai | -962.50K | 63.64% |
Aliran tunai bebas | -1.13J | 24.89% |
Perihal
Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate, Donna E. Davies and Ratko Djukanovic. The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19.
Richard Marsden was appointed chief executive officer in September 2009. Wikipedia
Diasaskan
2003
Tapak web
Pekerja
36